As part of the agreement, the companies will jointly validate the biomarkers for a test that will use Thermo Fisher’s Oncomine Precision Assay, which runs on the new Ion Torrent Genexus System.
The test will be used globally to detect low-grade glioma (LGG) patients with isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations who may be eligible for Agios’ investigational inhibitor vorasidenib (AG-881).
Vorasidenib is currently under evaluation in the Phase III INDIGO study.
Thermo Fisher Scientific clinical next-generation sequencing and oncology president Garret Hampton said: “The speed of the Genexus System in combination with the Oncomine Precision Assay has the potential to change the pace in which those diagnosed with LGG can be stratified and directed to a potentially more effective treatment in the future.
“We are committed to collaborating with leading pharmaceutical partners to make precision medicine accessible to more patients everywhere.”
According to the agreement, Thermo Fisher will maintain the rights to commercialise the new test globally and seek clearance from the regulatory agencies.
The companies initiated a partnership in 2017 to develop and commercialise a CDx to identify patients with IDH1 mutant cholangiocarcinoma who may be eligible for Agios’ TIBSOVO (ivosidenib or AG-120) as part of ClarIDHy Phase III clinical study.
In March, Thermo Fisher partnered with Janssen Biotech to develop a CDx to identify variant-positive patients for enrolment into clinical trials focused on non-small cell lung cancer (NSCLC).